You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 3, 2024

Chartwell Rx Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for CHARTWELL RX, and what generic and branded alternatives to CHARTWELL RX drugs are available?

CHARTWELL RX has three hundred and seventy-seven approved drugs.

There is one tentative approval on CHARTWELL RX drugs.

Summary for Chartwell Rx
US Patents:0
Tradenames:264
Ingredients:251
NDAs:377

Drugs and US Patents for Chartwell Rx

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chartwell Rx TOLBUTAMIDE tolbutamide TABLET;ORAL 086574-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx QUINAPRIL HYDROCHLORIDE quinapril hydrochloride TABLET;ORAL 076803-001 Mar 2, 2005 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx DICLOFENAC SODIUM diclofenac sodium TABLET, DELAYED RELEASE;ORAL 074376-001 Sep 28, 1995 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx PHENTERMINE HYDROCHLORIDE phentermine hydrochloride CAPSULE;ORAL 088611-001 Jun 4, 1984 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx CIMETIDINE cimetidine TABLET;ORAL 074100-004 Jan 31, 1995 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx RIBASPHERE ribavirin CAPSULE;ORAL 076203-001 Apr 6, 2004 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Chartwell Rx PIOGLITAZONE HYDROCHLORIDE pioglitazone hydrochloride TABLET;ORAL 078383-002 Mar 12, 2013 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Chartwell Rx

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chartwell Rx MOBAN molindone hydrochloride TABLET;ORAL 017111-006 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Try a Trial
Chartwell Rx MOBAN molindone hydrochloride TABLET;ORAL 017111-004 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Try a Trial
Chartwell Rx LIMBITROL amitriptyline hydrochloride; chlordiazepoxide TABLET;ORAL 016949-001 Approved Prior to Jan 1, 1982 4,316,897 ⤷  Try a Trial
Chartwell Rx MOBAN molindone hydrochloride TABLET;ORAL 017111-005 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Try a Trial
Chartwell Rx MOBAN molindone hydrochloride TABLET;ORAL 017111-007 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Try a Trial
Chartwell Rx MOBAN molindone hydrochloride TABLET;ORAL 017111-008 Approved Prior to Jan 1, 1982 3,491,093 ⤷  Try a Trial
Chartwell Rx LIMBITROL DS amitriptyline hydrochloride; chlordiazepoxide TABLET;ORAL 016949-002 Approved Prior to Jan 1, 1982 4,316,897 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.